MIRA Pharmaceuticals announces promising preclinical results for Ketamir-2, a novel oral ketamine analog for neuropsychiatric disorders treatment.
MIRA Pharmaceuticals announces promising preclinical results for its novel oral ketamine analog, Ketamir-2, optimized for brain delivery and avoiding ketamine's drug resistance. Ketamir-2 is under investigation for potential treatment of neurological and neuropsychiatric disorders such as depression and treatment-resistant depression. MIRA aims to submit an IND application to the FDA for human testing by the end of this year.
July 22, 2024
6 Articles